A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Clovis Oncology, Inc.
Sponsor:
Information provided by (Responsible Party):
Clovis Oncology, Inc.
ClinicalTrials.gov Identifier:
NCT02202746
First received: July 25, 2014
Last updated: September 29, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
Metastatic Breast Cancer
MBC
HER2 Positive
HER2+
Estrogen Receptor Positive
ER+
Triple Negative
Drug: Lucitanib
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Clovis Oncology, Inc.:

Primary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Screening, every 8 weeks; up to 2 years ] [ Designated as safety issue: No ]
    Defined as 1+ the number of days from the date of randomization to disease progression or death due to any cause, whichever occurs first


Secondary Outcome Measures:
  • Objective Response Rate (ORR) [ Time Frame: Screening, every 8 weeks; up to 2 years ] [ Designated as safety issue: No ]
    The best overall response recorded from the start of the treatment until disease progression or recurrence

  • Duration of Response (DR) [ Time Frame: Screening, every 8 weeks; up to 2 years ] [ Designated as safety issue: No ]
    DR for CR and PR will be measured from the date that any of these best responses is first recorded until the first date that PD is objectively documented

  • Disease Control Rate (DCR) [ Time Frame: Screening, every 8 weeks; up to 2 years ] [ Designated as safety issue: No ]
    The percentage of patients with a best response rate of CR, PR, or SD for at least 12 weeks

  • Overall Survival (OS) [ Time Frame: Continuously; up to 2 years ] [ Designated as safety issue: No ]
    Defined as 1+ the number of days from the date of randomization to death due to any cause

  • Safety Analyses [ Time Frame: Continuously; up to 2 years ] [ Designated as safety issue: Yes ]
    Incidence of adverse events (AEs), clinical laboratory abnormalities, and cardiac function, performed on all patients who have received at least one dose of lucitanib


Estimated Enrollment: 160
Study Start Date: July 2014
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lucitanib (CO-3810) 10 mg daily Drug: Lucitanib
Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1/2), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Other Name: CO-3810
Experimental: Lucitanib (CO-3810) 15 mg daily Drug: Lucitanib
Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1/2), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Other Name: CO-3810

Detailed Description:

Lucitanib is a selective orally available tyrosine kinase inhibitor targeting FGFR1,2, VEGFR1-3, and PDGFRα and β, with activity in relevant cell lines and animal models.

The first in human trial of lucitanib demonstrated that 15 mg of lucitanib given daily, can provide durable clinical responses in cancer patients with alterations of the FGF pathway. It has been noted, however, that for many patients, 15 mg daily is difficult to sustain beyond 3 cycles and dose reductions are frequently required. As such, this study will determine whether a starting dose of 10 mg of lucitanib daily is better tolerated and provides similar antitumor activity than 15 mg in patients with FGF aberrant advanced breast cancer, as measured by PFS.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic breast cancer relapsed or refractory to approved standard available treatment
  • Prior treatment with standard first line therapy in the metastatic setting
  • FGFR1 amplification or 11q (FGF3, FGF4, Cyclin D1, or FGF19) amplification
  • Demonstrated progression of disease by radiological or clinical assessment (Measurable disease according to RECIST Version 1.1 is NOT required for enrollment)
  • Estimated life expectancy >6 months

Exclusion Criteria:

  • Current or recent treatment with biologic anticancer therapies
  • Ongoing AEs from prior anticancer therapies
  • Active central nervous system (CNS) metastases
  • Clinically significant or uncontrolled hypertension or cardiac disease
  • Females who are pregnant or breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02202746

Contacts
Contact: Clovis Oncology Clinical Trial Navigation Service 1-855-262-3040 (USA) clovistrials@emergingmed.com
Contact: Clovis Oncology Clinical Trial Navigation Service +1-303-625-5160 (ex-USA) clovistrials@emergingmed.com

Locations
United States, California
Comprehensive Blood and Cancer Center Not yet recruiting
Bakersfield, California, United States, 93309
Contact: Lourdes Estrada    661-862-7178    lestrada@cbccusa.com   
Principal Investigator: Ravindranath Patel, MD         
United States, Illinois
Northwestern University, Robert H. Lurie Comprehensive Cancer Center Not yet recruiting
Chicago, Illinois, United States, 60611
Contact: Lauren Bontemps    312-695-1387    lauren.bontemps@northwestern.edu   
Principal Investigator: William Gradishar, MD         
University of Chicago Medical Center Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Alexandra Burleigh    773-834-9774    aburleigh@medicine.bsd.uchicago.edu   
Principal Investigator: Rita Nanda, MD         
United States, Indiana
Indiana University Simon Cancer Center Not yet recruiting
Indianapolis, Indiana, United States, 46202
Contact: LaTrice Vaughn    317-278-3730    lgvaughn@iupui.edu   
Principal Investigator: Kathy Miller, MD         
Horizon Oncology Center Recruiting
Lafayette, Indiana, United States, 47905
Contact: Beth Morris    765-446-5111 ext 19107    emorris@horizonbioadvance.com   
Principal Investigator: Wael Harb, MD         
United States, Tennessee
Sarah Cannon Cancer Center Recruiting
Nashville, Tennessee, United States, 37203
Contact: Emily Angarole    615-524-4086    emily.angarole@scresearch.net   
Principal Investigator: Denise Yardley, MD         
United States, Texas
US Oncology Recruiting
Houston, Texas, United States, 77024
Contact: Joshua Johnson    281-863-6731    joshua.johnson@mckesson.com   
Principal Investigator: Frankie Holmes, MD         
Sponsors and Collaborators
Clovis Oncology, Inc.
  More Information

No publications provided

Responsible Party: Clovis Oncology, Inc.
ClinicalTrials.gov Identifier: NCT02202746     History of Changes
Other Study ID Numbers: CO-3810-025
Study First Received: July 25, 2014
Last Updated: September 29, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Clovis Oncology, Inc.:
Breast cancer
Metastatic breast cancer
MBC
HER2 positive
HER2+
Estrogen receptor positive
ER+
Triple negative
FGFR1
11q
FGF aberrant

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on October 01, 2014